Nodule heterogeneity as shown by size differences between the targeted nodule and the tumor in thyroidectomy specimen: a cause for a false-negative diagnosis of papillary thyroid carcinoma on fine-needle aspiration.

Department of Pathology, University of Michigan, Ann Arbor, Michigan 48109-0054, USA.
Cancer (Impact Factor: 4.89). 02/2008; 114(1):27-33.
Source: PubMed


Missed papillary thyroid carcinoma (PTC) diagnoses on fine-needle aspiration (FNA) can result from many causes. To the authors' knowledge, the issue of whether the detection of PTC is correlated with nodule heterogeneity has not been studied to date.
The authors identified all thyroidectomy specimens with a diagnosis of PTC that had undergone at least 1 prior FNA in the study institution between 1998 and 2003. The tumor size at the time of the resection, the ultrasound (US)-determined nodule size, and other parameters were compared between the 2 groups in which PTC was or was not diagnosed on FNA.
Of a total of 89 specimens, 47 were diagnosed on FNA with an average tumor size of 1.7 cm and an US-determined nodule size of 2.1 cm (a difference of 0.4 cm). Forty-two specimens with a smaller average tumor size of 0.9 cm (P < .0001) and a US-determined nodule size of 2.4 cm (a difference of 1.5 cm) were missed. The differences with regard to the US-determined nodule size and tumor size between the 2 groups were significant (0.4 cm vs 1.5 cm; P < .0001). In the missed group, 29 specimens were found to have PTC foci that measured < or = 1.0 cm and 26 had a reasonable size difference (RSD; defined as a PTC size outside the range of +/-50% of the US-determined nodule size) as the indicator of the mixed nature of nodules targeted for FNA, whereas in the diagnostic group, 9 foci measured < or = 1.0 cm and 6 had RSD. There was no cytologic evidence with which to render a diagnosis of PTC on further review in the missed group.
The major reason for a missed diagnosis of PTC on FNA is because of inadequate tumor sampling due to the heterogeneity of the nodule targeted for FNA. This is illustrated by the RSD noted between the targeted nodule and the actual PTC tumor focus in the resection specimen.

1 Follower
113 Reads
  • Source
    • "There are also attempts to identify factors which increase the risk of false negative results (FN) and may be the indication to perform repeat FNA. These factors are said to include, among others, small size of the nodule, its difficult localization that lowers chances for precise aspiration, mixed cystic-solid character of the nodule, and large size of the nodule (>3-4 cm) which lowers probability of the aspirate representativeness [9] [10] [11]. In this study we decided to consider another such possible factor, that is, coexistence of the thyroid nodule with chronic lymphocytic thyroiditis (CT). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose. The aim of the study was to compare the risk of thyroid malignancy and efficacy of repeat FNA in patients with thyroid nodules diagnosed cytologically as benign lesion (BL) with features of chronic thyroiditis (BL-CT) and BL without CT features (BL-nCT). Methods. The analysis included 917 patients with BL-CT and 7046 with BL-nCT in the first FNA. Repeat biopsy was carried out in 787 patients of BL-CT and 5147 of BL-nCT; 218 patients of BL-CT and 2462 of BL-nCT were operated; in 88 cases of BL-CT and 563 of BL-nCT both ways of follow-up were available. Results. Outcome of repeat cytology implied surgery more frequently in patients with BL-CT than with BL-nCT-3.2% versus 1.9%, P < 0.05. Incidence of cancer (including incidentalomas) was higher in patients with BL-CT operated after one benign cytology than in patients with two benign FNA outcomes: 10.8% versus 1.6%, P < 0.05. In patients with BL-nCT that difference was not significant: 3.2% versus 2.6%. Conclusions. Patients with thyroid nodules diagnosed as BL with CT features have higher risk of malignancy than patients with BL without CT features. Repeat biopsy significantly lowers percentage of FN results in patients with BL-CT in the first FNA.
    International Journal of Endocrinology 04/2014; 2014(1):967381. DOI:10.1155/2014/967381 · 1.95 Impact Factor
  • Source
    • "nodules greater than 3 cm [9] [11] [12]. Due to this recommendation , the utility of FNAB has been gaining importance as a diagnostic aid in the management of thyroid nodules. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background. The purpose of this study was to assess the factors that affect the false-negative outcomes of fine-needle aspiration biopsies (FNABs) in thyroid nodules. Methods. Thyroid nodules that underwent FNAB and surgery between August 2005 and January 2012 were analyzed. FNABs were taken from the suspicious nodules regardless of nodule size. Results. Nodules were analyzed in 2 different groups: Group 1 was the false-negatives (n = 81) and Group 2 was the remaining true-positives, true-negatives, and false-positives (n = 649). A cytopathologist attended in 559 (77%) of FNAB procedures. There was a positive correlation between the nodule size and false-negative rates, and the absence of an interpreting cytopathologist for the examination of the FNAB procedure was the most significant parameter with a 76-fold increased risk of false-negative results. Conclusion. The contribution of cytopathologists extends the time of the procedure, and this could be a difficult practice in centres with high patient turnovers. We currently request the contribution of a cytopathologist for selected patients whom should be followed up without surgery.
    International Journal of Endocrinology 06/2013; 2013:126084. DOI:10.1155/2013/126084 · 1.95 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The assessment of a thyroid nodule serves several purposes. The patient may experience symptoms from a functional or sizable lesion, or may be at risk of cancer. A thorough history and blood test for TSH, eventually combined with a technetium (Tc) scan, will promptly identify a hyperfunctioning nodule. Symptoms related to the size of a nodule are usually indicated by the patient, and may be crucial in the treatment-making process.
    12/2008: pages 17-28;
Show more


113 Reads
Available from